Inventor · disambiguated record
Alison Jones
Also filed as: JONES ALISON
24 granted patents·2 pending applications·49 citations·filing 2008–2022
93Inventor score
Top patents by PatentIndex Score
26 records- 0194US9926307B2CompoundsMISSION THERAPEUTICS LTD·Filed 2015·Granted Mar 27, 2018·14 cites·16 claims
- 0293US10343992B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2016·Granted Jul 9, 2019·7 cites·2 claims
- 0392US10689345B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·4 cites·14 claims
- 0489US10392380B2CompoundsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 27, 2019·6 cites·17 claims
- 0587US10774078B2CompoundsMISSION THERAPEUTICS LTD·Filed 2019·Granted Sep 15, 2020·2 cites·10 claims
- 0686US11472798B2CompoundsMISSION THERAPEUTICS LTD·Filed 2020·Granted Oct 18, 2022·1 cites·11 claims
- 0785US10640498B2CompoundsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 5, 2020·6 cites·17 claims
- 0883US11390584B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Jul 19, 2022·1 cites·14 claims
- 0981US11993595B2CompoundsMISSION THERAPEUTICS LTD·Filed 2022·Granted May 28, 2024·0 cites·10 claims
- 1078US9296725B2Heterocyclyl pyrimidine analogues as TYK2 inhibitorsCELLZOME LTD·Filed 2013·Granted Mar 29, 2016·6 cites·16 claims
- 1178US2022251041A11-cyano-pyrrolidine compounds as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1273US10669234B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2016·Granted Jun 2, 2020·1 cites·15 claims
- 1372US10683269B22-cyanoisoindoline derivatives for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 16, 2020·1 cites·15 claims
- 1470US11066365B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 20, 2021·0 cites·14 claims
- 1570US11053198B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·0 cites·4 claims
- 1670US2022106315A1Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1768US11945797B21-cyano-pyrrolidine derivatives as dub inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Granted Apr 2, 2024·0 cites·15 claims
- 1866US11236092B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Feb 1, 2022·0 cites·10 claims
- 1960US11319287B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·0 cites·15 claims
- 2053US10654853B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 19, 2020·0 cites·10 claims
- 2148US11352339B21-cyano-pyrrolidine derivatives as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 7, 2022·0 cites·15 claims
- 2247US8692017B2Carbon linked modulators of gamma-secretaseHO CHIH YUNG·Filed 2008·Granted Apr 8, 2014·0 cites·10 claims
- 2346US8247610B2Amine linked modulators of γ-secretaseHO CHIH YUNG·Filed 2008·Granted Aug 21, 2012·0 cites·6 claims
- 2441US11014912B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted May 25, 2021·0 cites·17 claims
- 2540US11306096B24,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Apr 19, 2022·0 cites·11 claims
- 2640US9655897B2Heterocyclyl pyrimidine analogues as TYK2 inhibitorsCELLZOME LTD·Filed 2016·Granted May 23, 2017·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Alison Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →